If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Khavinson immune / endocrine short-peptide bioregulator
Supply and ordering
Ask sales about Crystagen availability, order quantities, packaging, and batch documentation. Include other catalog items in the same inquiry if you are planning a combined or recurring order.
Overview
Crystagen is a Khavinson-class short-peptide bioregulator positioned within the Khavinson framework as the immune and endocrine regulatory peptide, targeting thymic and endocrine-tissue gene-expression programs under the shared hypothesis of tissue-specific bioregulator activity. Crystagen complements the larger and more rigorously characterized immune-modulation peptides in the catalog (Thymosin Alpha-1, Thymulin) by occupying the Khavinson short-peptide niche for buyers specifically studying the Khavinson framework's hypothesis rather than the broader thymic-peptide pharmacology. PeptideXpo supplies Crystagen as a lyophilized 20 mg vial to a ≥99.0% HPLC purity specification. As with the rest of the Khavinson class, MS identity on the batch COA, with sequence verification on request, is essential because CAS is not consistently registered and the family members differ in tissue-specific positioning rather than analytical fingerprint. Buyers working with Crystagen should confirm the sequence matches their reference protocol via COA at batch receipt.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COACrystagen 20 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm sequence and identity per batch COA.
Selected literature
Frequently asked questions
Crystagen and Thymosin Alpha-1 occupy different research niches despite overlapping marketed indications. Thymosin Alpha-1 is a defined 28-amino-acid peptide with extensive Western peer-reviewed clinical-trial data and approved-drug status in 35+ jurisdictions, it is the appropriate choice for research workflows that need to align with published Western clinical data and rigorous mechanism-of-action literature. Crystagen is a Khavinson-class short peptide with research evidence concentrated in Russian-language journals, appropriate for buyers specifically studying the Khavinson bioregulator framework or replicating Russian-school protocols. The two are not chemically equivalent or pharmacologically interchangeable; choose based on which evidence base your research is aligning with.
Khavinson-school publications on Crystagen focus on thymic and endocrine-tissue gene-expression effects in animal models of age-related immune decline, with reported readouts on T-cell maturation markers, lymphocyte proliferation responses, and antibody-response capacity in aged-rodent models. The mechanism hypothesis within the Khavinson framework is that Crystagen acts as an endogenous-mimetic bioregulator of thymic-tissue gene expression, supporting the thymic-output capacity that declines with age and contributing to age-related immunosenescence. As with the broader Khavinson framework, the mechanism details are hypothesized rather than independently confirmed at the rigor level of Western mechanism-of-action research.
All three products occupy the thymic-immune-modulation space but with substantially different characterization. Thymulin is a defined 9-amino-acid zinc-binding peptide (CAS 63958-90-7), the most chemically defined of the three. Thymalin is a complex multi-peptide extract derived from bovine thymus tissue, similar in compositional nature to Cerebrolysin, a multi-component preparation rather than a single molecule. Crystagen is a Khavinson-class short peptide positioned as the synthetic-simplified version of the thymic-tissue regulatory peptides. Buyers should be explicit at order placement about which they want, the three products are not chemically interchangeable, and the applicable batch COA should identify which compositional class the released material represents.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
Thymic immune-modulation peptide(s)
Nasal spray available
4-mer
Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
